{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071385","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.687220+00:00","generated_at":"2026-05-21T09:31:19.571340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acrivon's ACR-368 shows 35% cORR in endometrial cancer; cash $164.8M","bullets":["Q1 2025 net loss $19.7M vs $16.5M YoY; R&D spend $15.4M on trial advancement.","Cash, equivalents and securities $164.8M; runway into Q2 2027.","ACR-368 Phase 2b: 35% cORR, 80% DCR in OncoSignature+ patients; 50% cORR in relapsed subset.","ACR-2316 Phase 1: DL4 enrolling; ~25% tumor shrinkage at DL3 below projected RP2D.","Appointed Mansoor Raza Mirza as CMO; promoted Adam Levy to CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071385","json":"https://secwatch.observer/filing/0000950170-25-071385.json","markdown":"https://secwatch.observer/filing/0000950170-25-071385.md","text":"https://secwatch.observer/filing/0000950170-25-071385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/0000950170-25-071385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/acrv-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:31:19.571340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}